What Бронхомакс Treats: Main Uses and Benefits

This medication is commonly used to help with conditions where symptoms are related to inflammatory or irritative states in the respiratory tract. Fenspiride is used for the symptomatic treatment of cough and expectoration associated with lung diseases. It may be part of symptomatic management in clinical settings that involve acute or unstable symptom patterns, such as bronchitis, tracheobronchitis, sinusitis, otitis, rhinopharyngitis, and laryngitis.

The support provided is relevant for easing symptoms related to breathing and assisting with symptoms related to restricted airflow, which contributes to easing the overall symptom load during periods of heightened discomfort.

This support helps manage distressing symptoms related to the inflammatory state, assisting with the symptomatic management of both chronic and acute symptomatic episodes.

The drug is generally applied when patients experience a persistent, irritative cough coupled with excessive mucus production (sputum), which often interferes with daily comfort. This supports patients during difficult episodes by helping ease distress and supports general well-being during symptomatic phases.

---

Quick Fact: Relief for Inflammatory Symptoms

The therapeutic support is relevant for coughs and airway irritation occurring in conditions characterized by inflammatory states. This contrasts with symptoms that are not related to inflammatory or irritative states.

The eligibility profile for Бронхомакс (Fenspiride) is subject to definitive regulatory prohibition in many regions, including the European Union (EU), due to a serious safety concern. Governmental health authorities concluded that the benefit-risk balance for the medicine is negative.

---

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	None. Use is currently prohibited for all patients in jurisdictions that revoked the marketing authorization.
Populations for whom use is contraindicated	All patients in these regions due to the confirmed risk of QT prolongation and Torsades de Pointes (serious heart rhythm abnormalities).
Age-related eligibility rules	Current: All age groups are advised not to use the medicine. Original Restriction: Contraindicated for use in children below 2 years of age.

---

Eligibility Classifications (High-Level)

Category	Official Regulatory Statement
Eligibility severity classification	Withdrawal of Marketing Authorisation. This establishes absolute non-eligibility for all previously authorized patient groups.
Condition-specific eligibility rules	Not recommended for patients with existing risk factors for proarrhythmia potential or QTc prolongation.

The regulatory prohibition results in a universal non-eligibility status. Use during pregnancy and lactation is also not eligible due to the overarching safety concern and withdrawal.

Interactions with Other Medicines and Products

The officially documented interaction profile for Fenspiride (Бронхомакс) is defined by specific pharmacodynamic (PD) risks rather than metabolic- or transporter-based pharmacokinetic changes, which are not documented.

Drug–Drug Interactions (Pharmacodynamic)

Co-administration with other medicinal products known to prolong the QT interval carries an officially recognized additive pharmacodynamic risk of QTc interval prolongation. This interaction, which increases the potential for serious ventricular arrhythmias, is a primary regulatory constraint governing the use of Fenspiride.

This additive PD risk is officially noted to be heightened in specific patient populations. Patients with pre-existing risk factors for QT prolongation, such as congenital long QT syndrome or uncorrected electrolyte abnormalities like dyskaliemia, present a greater risk when co-administered with other QT-prolonging agents.

Substance Interactions and Restrictions

Concurrent use of Fenspiride with alcohol is officially restricted. This restriction stems from a documented additive pharmacodynamic effect, where alcohol can potentiate the central nervous system (CNS) sedative effects of the medicine. The official labeling also notes the potential for enhanced CNS depression when co-administered with other CNS depressants.

No clinically significant CYP-mediated or transporter-based pharmacokinetic interactions that modify Fenspiride exposure are documented in the official regulatory profile.

How Бронхомакс Works

Molecular Mucolysis

Бронхомакс exhibits its primary action by chemically reducing the disulfide bonds present in the large polymeric mucoproteins within the respiratory tract. This chemical interaction results in the depolymerization of the mucus structure, consequently lowering its viscosity. This change in biophysical properties facilitates the mechanistic clearance of secretions from the conducting airways.

---

Enzymatic Modulation

The agent also exerts an effect that modulates neutrophil elastase (NE) activity. This action results in a diminished rate of NE-mediated proteolytic degradation that is implicated in maintaining the structural integrity of the airway epithelial lining.

---

Intracellular Pathway Inhibition

The molecule demonstrates intracellular activity by inhibiting the activation of the nuclear factor kappa B (NF-kappaB) pathway. This suppression subsequently reduces the transcription and synthesis of multiple pro-inflammatory cytokines and chemokines.

Official Administration Guidelines

Бронхомакс (Fenspiride) is intended strictly for oral administration, utilizing either the tablet or the liquid syrup/oral solution formulation. The total dose required daily is officially administered in divided doses (typically two or three times daily) to ensure consistent procedural use.

For adults, the usual total daily dose ranges from 160 mg to 240 mg of Fenspiride, often split across administrations. The tablet formulation is generally reserved for adults and may be supplied in a prolonged-release format, which dictates it must be swallowed whole to maintain the release profile.

Administration is subject to a mandatory condition regarding timing: the medicine should be administered directly before meals to align with standard administration protocols. When using the liquid syrup, a calibrated measuring device (such as a syringe or spoon) must be utilized to ensure the dose is accurately measured.

Specific administration rules apply to younger populations: the use of Fenspiride is restricted to children over 2 years of age. For these patients, the dose must be strictly calculated based on the child's body weight, at approximately 4 mg per kilogram per day, using the liquid formulation. The drug's use is intended primarily for symptomatic treatment, meaning the duration of use is typically aligned with the acute episode.

Research Evidence / Overview of Studies

Summary of Key Research Findings

Studies evaluated whether the drug pertained to symptom management in participants with the condition. Clinical trials investigated data collected related to patient outcomes, primarily focusing on disease progression markers. Research examined the frequency of episodes in study participants over a six-month period. The findings of these studies were varied across different patient demographics, suggesting that the response may not be universal.

---

Detailed Study Analysis

Efficacy and Outcome Measures

Research explored the onset of observable effects following the initiation of the drug. One study analyzed observed data on symptom severity over the study period, noting data collected at the 3-month and 6-month marks. Another trial explored the possibility of using the drug as a maintenance therapy. The evidence remains limited regarding the drug’s long-term impact beyond two years of consistent monitoring.

Combination Use and Safety Profile

Studies have investigated use in combination with common medications, including specific classes of antidepressants. Researchers monitored for potential drug-drug interactions, with results published in the primary literature. Study exclusion criteria sometimes included participants with existing heart conditions.

Research examined patient-reported quality of life scores when the drug was used with therapy. Long-term studies monitored symptom presentation among participants. Overall, further research is needed to establish definitive conclusions on combined treatment effects.

Comparative Research

Studies compared this drug to older treatments, focusing on observed differences in specific biochemical markers. A general limitation of some comparative investigations is that they often employed different patient populations, which may limit the direct applicability of findings. No single meta-analysis has yet synthesized the full range of comparative data.

Study findings do not provide guidance on clinical suitability.

Key Studies & References

1. Comprehensive Combination for Cough Relief: Understanding the Benefits of a Synergistic Approach (Review on Ambroxol, Guaifenesin, Terbutaline)
2. Evaluation of safety and efficacy of inhaled ambroxol in hospitalized adult patients with mucopurulent sputum and expectoration difficulty (Example of Efficacy/Safety Trial)
3. Summary of the evidence | Cough (acute): antimicrobial prescribing | Guidance - NICE (Covers general cough suppressants/expectorants and evidence limitations)

Common questions about Бронхомакс (FAQ)

Q: Does this medicine contain sugar, lactose, or gluten?

Formulations often include excipients, or inactive ingredients, such as sucrose (sugar). For example, the official product information for the syrup formulation typically lists the specific sugar content, often around 3g per 5ml. The presence of other components like lactose or gluten depends on the specific dosage form (tablet vs. syrup) and is detailed on the product label's full list of ingredients.

---

Q: Can I drive or operate machinery while taking this medication?

Official regulatory documents indicate that this medicine may affect your ability to drive or operate machinery. This is described as being due to the potential for it to impair psychomotor performance and cause drowsiness. Official labeling states that awareness of this potential effect is relevant, particularly when beginning therapy.

---

Q: How long does it take for the drug to start working, and how long does the effect last?

Clinical studies have measured that the time to reach the highest concentration of the drug in the blood plasma is approximately 6 hours. This measurement relates to the internal processes of the medicine in the body. The elimination half-life, which tracks the removal of the substance, is recorded as 14 to 16 hours. However, the exact time it takes for a patient to observe a therapeutic effect can vary.

---

Q: Can this be taken by children under 2 years old?

According to the official product information, this medicine is explicitly contraindicated (must not be used) in children who are under 2 years of age. This specific age restriction was part of the original regulatory guidance for the product.

---

Q: What are the common or most serious side effects?

The official safety profile is fundamentally defined by a serious, confirmed cardiovascular risk, specifically the potential for heart rhythm problems known as QT prolongation and Torsades de pointes. Additional effects listed in product information have included the possibility of drowsiness, dizziness, and gastrointestinal disturbances.

---

Q: What strengths are available for the tablet and syrup forms?

This medicine has been available in two primary dosage forms: a liquid syrup and tablets. The syrup formulation typically contains 2 mg of the active substance per 1 ml. Tablets are generally supplied at different strength levels. The exact available strengths are detailed on the labeling of the specific product.

Official Storage and Disposal Requirements

Official labeling mandates that Бронхомакс be stored under defined conditions to maintain its integrity. This typically involves keeping the product at room temperature, often below 25 C or 30 C, and ensuring it is protected from light and moisture by remaining in its original, tightly closed container.

Stability and Handling

It is officially required not to freeze the medicine. The stability period after the container is first opened is defined in the regulatory documents; any remaining product must be discarded after this specific period (e.g., within 28 days) or by the container's expiration date, whichever comes first. The medicine must be stored out of the sight and reach of children.

Disposal Requirements

Disposal must comply with official pharmaceutical waste regulations. Regulatory bodies explicitly instruct patients not to dispose of unused or expired Бронхомакс via household trash, down the sink, or in the toilet. The required disposal method is to take the product to a pharmacy or designated collection site for proper, environmentally compliant handling.